Technology Transfer from Innovator to Generic CDMO: Process, Pitfalls, and Best Practices
Introduction Technology Transfer from Innovator to Generic CDMO is a structured and highly regulated process involving the systematic translation of […]
Bioanalytical CRO Services for Phase I First-in-Human Studies: Regulatory Requirements and Study Design
Introduction Bioanalytical CRO services for Phase I First-in-Human studies provide the quantitative bioanalytical infrastructure necessary to validate drug concentration assays,
Case Study: Nitrosamine Risk Assessment for a Proton Pump Inhibitor Seeking ANDA Approval
Introduction A comprehensive Nitrosamine Risk Assessment for a Proton Pump Inhibitor seeking Abbreviated New Drug Application (ANDA) approval requires a
Generic Drug Development for Inhaled Drug Products: MDI, DPI, and Nasal Spray ANDA Challenges at a CDMO
Introduction: Generic Drug Development for Inhaled Drug Products requires a development strategy that connects formulation science, device engineering, analytical characterization,
Sequence Confirmation Services for Synthetic Therapeutic Peptides: From Research Batches to GMP Lots
Introduction Sequence Confirmation Services for Synthetic Therapeutic Peptides provide definitive verification of the primary amino acid sequence, terminal modifications, and
Automation in Peptide-Oligonucleotide Conjugate Synthesis
Introduction: Automation in Peptide-Oligonucleotide Conjugate Synthesis is becoming increasingly important as researchers seek more reproducible and scalable ways to manufacture
Automation in Peptide-Oligonucleotide Conjugate Synthesis Read More »
Peptide-Oligonucleotide Conjugate Drug Product Formulation Services: From Bulk API to Injectable Drug Product
Introduction Peptide-Oligonucleotide Conjugate Drug Product Formulation Services address the complex development transition between bulk active pharmaceutical ingredient (API) bioconjugation and
Next-Generation Oligonucleotide Chemistries in Peptide-Oligonucleotide Conjugates Design: LNA, PNA, and Morpholino Modifications
Introduction Peptide-oligonucleotide conjugates depend on Next-Generation Oligonucleotide Chemistries to address the limitations associated with native enzymatic degradation, inadequate cellular permeability,
Case Study: Generic Topical Semisolid ANDA — Formulation Equivalence, Dissolution, and Q1/Q2 Sameness
Introduction Demonstrating bioequivalence for a Generic Topical Semisolid ANDA requires a comprehensive assessment of qualitative (Q1), quantitative (Q2), and structural
What Regulatory Pathway Do Generic Peptide Drugs Follow — ANDA, 505(b)(2), or BLA?
Introduction Selecting the appropriate Generic Peptide Regulatory Pathway—whether an Abbreviated New Drug Application (ANDA) under Section 505(j), a hybrid New
What Regulatory Pathway Do Generic Peptide Drugs Follow — ANDA, 505(b)(2), or BLA? Read More »